We are committed to speeding up diagnosis

 

With the completion of the human genome reference sequence, along with the emergence of technologies like Next-Generation Sequencing (NGS) and the development of bioinformatics technology for efficient analysis and processing of massive biological data, the molecular diagnostic efficiency of rare diseases has indeed seen a rapid improvement in recent years. Great breakthroughs have been made in technical methods, providing technical guarantees for genetic counseling for patients and clinicians and laying a foundation for future gene therapy. Currently, among numerous genome technologies, NGS technology stands out and plays an important role in the study of genetic rare diseases due to its unique advantages.

Whole Exome Sequencing

The diagnosis rate is twice that of chromosomal microarray (cma) and multigene panels.

DiaWES

Faster diagnosis with comprehensive genetic testing

Whole Genome Sequencing

The most comprehensive genetic testing, including mitochondrial genome sequencing.

WGS

Comprehensive Testing, Precise Answers

 

Powered by advanced genetic testing technology, unparalleled internal database, and extensive clinical expertise, MyGenostics' industry-leading tests can provide clinically actionable results faster.

Learn More 뀠

About MyGenostics

MyGenostics Technology Co., Ltd.  was established in 2011, and is a national high-tech enterprise that provides high-throughput gene sequencing comprehensive solutions integrating research, production, and sales. MyGenostics takes its proprietary "Gencap gene capture" technology as its core, combining the next-generation high-throughput sequencing technology, and has developed over 400 personalized gene capture LDT and IVD kits. Its products are widely used in assisted diagnosis and screening of genetic diseases, cancer drug use, microbial identification, etc., greatly enhancing the clinical detection and scientific research capabilities related to systemic diseases. The company has been granted 128 patents and software copyrights, and has established long-term and stable cooperative relationships with over 500 tertiary hospitals nationwide and more than 6,000 doctors. It has published 924 SCI academic papers and has built the largest genetic disease database of over 400,000 people in the industry.

  • ꁸ 回到顶部
  • ꂅ 400-003-5255
  • ꁗ QQ客服
  • ꀥ 官方公众号
All rights reserved © Beijing Mygenostics co., LTD